Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 4,406 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: medical therapy Clear all
Completed Not applicable Interventional

Intervention to Reduce Perceived Cognitive Impairment in Multiple Sclerosis

NCT03889327
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Neuropsychological Feedback & Psychoeducation (Cognition), Psychoeducation (Health)
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

NCT01902173
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Magnetic Resonance Imaging, Trametinib Dimethyl Sulfoxide, Uprosertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 10, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional

NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

NCT06593327
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Cardiomyopathy, Heart Failure, Cardiometabolic Diseases
Interventions
Intensive Prevention Strategy
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Phase 3 Interventional

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

NCT00401362
View directory record Official record
Conditions
Advanced Illness Patients With Opioid Induced Constipation
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 10, 2026, 5:58 AM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NCT07504588
View directory record Official record
Conditions
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Echocardiography Test, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Sacituzumab Govitecan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System

NCT03950986
View directory record Official record
Conditions
Influenza, Tetanus, Diphtheria, Pertussis, Pneumonia
Interventions
Modified clinical reminders
Other
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
Not listed
Enrollment
67,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 10, 2026, 5:58 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Multiple Component Mobile-aid Pain Reduction Intervention to Decrease Myofascial Pain

NCT05860205
View directory record Official record
Conditions
Myofascial Pain Syndrome
Interventions
Multiple Component Mobile-Aid Pain Reduction Intervention, Osteopathic Manipulation Treatment, Sham Osteopathic Manipulation
Behavioral · Other
Lead sponsor
Kailea Manning
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 10, 2026, 5:58 AM EDT
Completed No phase listed Observational

Guideline Directed Medical Therapy in Patients With Heart Failure

NCT06700213
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 10, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

NCT03907488
View directory record Official record
Conditions
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
711
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

NCT01035229
View directory record Official record
Conditions
Carcinoma
Interventions
Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 10, 2026, 5:58 AM EDT
Recruiting No phase listed Observational

FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions

NCT07749170
View directory record Official record
Conditions
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Supportive Care for Patients Newly Diagnosed With Lung Cancer

NCT01883986
View directory record Official record
Conditions
Lung Cancer
Interventions
Palliative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation for Alcohol Use Disorder

NCT05522751
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
DBS
Device
Lead sponsor
Khaled Moussawi
Other
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Not applicable Interventional Results available

Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers

NCT01353495
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
APM Graft (BIOTAPE XMTM), Wound Debridement
Device · Other
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fresno, California • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 10, 2026, 5:58 AM EDT
Completed No phase listed Observational

Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer

NCT00711672
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Hematology and Oncology Associates of NE Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dunmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of HIV Testing and Linkage to Care at Community Corrections

NCT01366495
View directory record Official record
Conditions
HIV
Interventions
Project Bridge
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
797 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 10, 2026, 5:58 AM EDT
Not listed Not applicable Interventional

Randomized Control Trial (RCT) of Early Palliative Care for HCC

NCT02556619
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Early Palliative Care/Symptom Control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 10, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

NCT06138067
View directory record Official record
Conditions
Prostate Cancer, Kidney Cancer
Interventions
High intensity approach, Low intensity approach
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Chambersburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Results available

Rocklatan® Evaluation

NCT05283395
View directory record Official record
Conditions
Glaucoma
Interventions
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Mission Hills, California • Newport Beach, California • Pasadena, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 10, 2026, 5:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

NCT06390839
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Completed No phase listed Observational

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT05841030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 10, 2026, 5:58 AM EDT
Recruiting Early Phase 1 Interventional

Concomitant Renal and Urinary Bladder Allograft Transplantation

NCT04626167
View directory record Official record
Conditions
Chronic Kidney Diseases, Bladder Dysfunction, Bladder Absence, Posterior Urethral Valve, Neurogenic Bladder, Bladder Exstrophy, Bladder Outlet Obstruction, Failure, Kidney, Transplant
Interventions
Concomitant Renal and Urinary Bladder Allograft Transplantation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 10, 2026, 5:58 AM EDT
Terminated Early Phase 1 Interventional

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

NCT04630353
View directory record Official record
Conditions
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
HB-201 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 5:58 AM EDT